We are now well above 75k exomes and thousands of phenotypes. Work is going very well; we have made major inroads towards understanding the genetic basis of several diseases but have focused largely on immune and cardiometabolic traits in the main. Our first major publication was CLAMMS, by far the most efficient versatile and scalable exome-specific CNV caller out there. Additional publications are in review and I will put the link up when the articles go live. Here's to another great year of great science!

I'm delighted to announce today that I'll soon be starting a new position in the Regeneron Genetics Center as Manager, Statistical Genetics! Will post some updates over the coming months. The overall aim of the company's work will be to leverage human genetics, through exome and related studies and numerous collaborations, to inform on new drug targets. See here for original press release and here for the company's website. Very excited about the challenges and opportunities that lie ahead. 

Big big news this week in nature. I was a small part of this work. I believe there's still about 15-20 years ahead before we have new families of genetics-informed drugs for schizophrenia, but this is a major advance. It's sort of a human genome project for schizophrenia, identifying a large number of the genes implicated in the condition and setting forth an initial road map for drug development. 

Check it out here: http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2742.html 

Once of my resolutions will be to actually update this site at a reasonable rate...

Yikes, I haven't updated in a long time. Work going well. Exciting conference in Hamburg a month ago where we saw how successful GWAS was becoming for SCZ in particular. An example is below, highlighting emerging genomewide significant loci in schizophrenia over just 3 years!

- Working full time at the Broad now, going very well

- Working on pooled sequencing data this week